VYNE Therapeutics is a pharmaceutical company. Co.'s products include AMZEEQ® (minocycline) topical foam, 4% for the treatment of inflammatory lesions of moderate-to-severe acne vulgaris in adults and patients nine years of age and older, and ZILXI® (minocycline) topical foam, 1.5% for the treatment of inflammatory lesions of rosacea in adults. Co.'s product pipeline includes FCD105 (minocycline 3% and adapalene 0.3%), its proprietary topical combination foam formulation of minocycline and adapalene for the treatment of moderate-to-severe acne vulgaris. In addition, Co.'s development program, FMX114, is a combination topical gel for the treatment of mild-to-moderate atopic dermatitis. The VYNE stock yearly return is shown above.
The yearly return on the VYNE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VYNE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|